Review ArticlesOligometastatic and Oligoprogression Disease and Local Therapies in Prostate CancerDeek, Matthew P. MD∗; Tran, Phuoc T. MD, PhD∗,†,‡Author Information From the Departments of ∗Radiation Oncology and Molecular Radiation Sciences †Urology ‡Program in Cancer Invasion and Metastasis, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Reprints: Phuoc T. Tran, MD, PhD. 1500 Orleans Street, CRB2 Rm 406, Baltimore, MD 21231. E-mail: email@example.com. The Cancer Journal: 3/4 2020 - Volume 26 - Issue 2 - p 137-143 doi: 10.1097/PPO.0000000000000432 Buy Metrics Abstract Our understanding of metastatic disease is rapidly advancing, with recent evidence supporting an oligometastatic state currently defined by patients having a limited (typically ≤5) number of metastatic deposits. The optimal management of these patients is also shifting toward increased integration of local therapies, with emerging evidence suggesting metastasis-directed therapy can improve overall survival. Additionally, the use of stereotactic ablative radiation therapy within castration-sensitive oligometastatic prostate cancer cohorts appears to forestall the need to initiate systemic therapy, which has unfavorable side effect profiles, such as androgen deprivation therapy, while itself being associated with little toxicity. We review the literature surrounding the use of metastasis-directed therapy in the treatment of oligometastatic prostate cancer by reviewing the evidence for its use within 3 subgroups: de novo synchronous, oligorecurrent, and oligoprogressive disease. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.